Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease. 1 The term “pemphigoids” refers to a group of autoimmune bullous diseases characterized by subepidermal ...

What disorders should be included in the differential diagnosis of a 91-year-old white woman with acute onset of bullous-appearing lesions on the tips of her index, middle, ring, and fifth fingers ...

People with bullous pemphigoid are typically given topical or oral steroids to treat the “tense blisters” that show up on the arms, legs, lower body and occasionally in the mouth.

Bullous pemphigoid is a rare autoimmune disease that causes painful chronic blisters and welts. it typically strikes elderly people who already have one or more diseases or are in poor health.

Bullous pemphigoid should be included in the differential diagnosis list of blistering skin lesions of the Yucatan minipig. Return to Case. References.

Corticosteroid-refractory bullous pemphigoid is very rare in children, but in such cases, dapsone, mycophenolate mofetil, cyclosporine, azathioprine, plasmapheresis and rituximab may be good ...

Pronounced “BULL-us PEM-fih-goyd” (with bullous being the medical term for a large blister), Bullous Pemphigoid is a rare, autoimmune, chronic skin disorder that causes large, fluid-fil… ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with systemic corticosteroids, Sanofi and Regeneron announced. The FDA’s ...

Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. If untreated, it can persist for months or years, with periods of spontaneous remissions and exacerbations.

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly ...